{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T07:34:27Z","timestamp":1747208067003,"version":"3.40.5"},"reference-count":135,"publisher":"Becaris Publishing Limited","issue":"6","funder":[{"name":"Janssen Global Services"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:p>\n            <jats:bold>Introduction:<\/jats:bold>\n            Treatment of amyloid light-chain (AL) amyloidosis, a rare disease with a &lt;5-year lifespan, remains challenging. This systematic literature review (SLR) aimed to evaluate the current evidence base in AL amyloidosis.\n            <jats:bold>Methods:<\/jats:bold>\n            Literature searches on clinical, health-related quality of life, economic and resource use evidence were conducted using the Embase, MEDLINE and Cochrane databases as well as gray literature.\n            <jats:bold>Results:<\/jats:bold>\n            This SLR yielded 84 unique studies from: five randomized controlled trials; 54 observational studies; 12 health-related quality of life studies, none with utility values; no economic evaluation studies; and 16 resource use studies, none with indirect costs.\n            <jats:bold>Conclusion:<\/jats:bold>\n            This SLR highlights a paucity of published literature relating to randomized controlled trials, utility values, economic evaluations and indirect costs in AL amyloidosis.\n          <\/jats:p>","DOI":"10.2217\/cer-2021-0261","type":"journal-article","created":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T14:21:33Z","timestamp":1645453293000},"page":"451-472","source":"Crossref","is-referenced-by-count":2,"title":["Systematic literature review of evidence in amyloid light-chain amyloidosis"],"prefix":"10.57264","volume":"11","author":[{"given":"Charlene","family":"Lee","sequence":"first","affiliation":[{"name":"Janssen Global Services, LLC, Raritan, NJ\u00a008869, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annette","family":"Lam","sequence":"additional","affiliation":[{"name":"Janssen Global Services, LLC, Raritan, NJ\u00a008869, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Kangappaden","sequence":"additional","affiliation":[{"name":"EVERSANA Life Science Services, LLC, Burlington, ON, L7N 3H8, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pyper","family":"Olver","sequence":"additional","affiliation":[{"name":"EVERSANA Life Science Services, LLC, Burlington, ON, L7N 3H8, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Kane","sequence":"additional","affiliation":[{"name":"EVERSANA Life Science Services, LLC, Burlington, ON, L7N 3H8, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4207-7554","authenticated-orcid":false,"given":"Diana","family":"Tran","sequence":"additional","affiliation":[{"name":"EVERSANA Life Science Services, LLC, Burlington, ON, L7N 3H8, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5882-5388","authenticated-orcid":false,"given":"Eric","family":"Ammann","sequence":"additional","affiliation":[{"name":"Janssen Global Services, LLC, Raritan, NJ\u00a008869, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"36897","reference":[{"issue":"6","key":"e_1_3_3_3_2","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.2215\/CJN.02740806","article-title":"Light-chain (AL) amyloidosis: diagnosis and treatment","volume":"1","author":"Sanchorawala V","year":"2006","unstructured":"Sanchorawala V. Light-chain (AL) amyloidosis: diagnosis and treatment. Clin. J. Am. Soc. Nephrol. 1(6), 1331\u20131341 (2006).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"e_1_3_3_4_2","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.12688\/f1000research.15353.1","article-title":"Recent advances in understanding and treating immunoglobulin light chain amyloidosis","volume":"7","author":"Badar T","year":"2018","unstructured":"Badar T, D'souza A, Hari P. Recent advances in understanding and treating immunoglobulin light chain amyloidosis. F1000Res. 7, 1348 (.2018).","journal-title":"F1000Res."},{"issue":"2","key":"e_1_3_3_5_2","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1159\/000495455","article-title":"Recent advances in the diagnosis, risk stratification, and management of systemic light-chain amyloidosis","volume":"141","author":"Vaxman I","year":"2019","unstructured":"Vaxman I, Gertz M. Recent advances in the diagnosis, risk stratification, and management of systemic light-chain amyloidosis. Acta Haematol. 141(2), 93\u2013106 (2019).","journal-title":"Acta Haematol."},{"key":"e_1_3_3_6_2","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.3389\/fphar.2019.01601","article-title":"Efficacy of chemotherapies and stem cell transplantation for systemic AL amyloidosis: a network meta-analysis","volume":"10","author":"Cai Y","year":"2019","unstructured":"Cai Y, Xu S, Li N, Li S, Xu G. Efficacy of chemotherapies and stem cell transplantation for systemic AL amyloidosis: a network meta-analysis. Front. Pharmacol. 10, 1601 (2019).","journal-title":"Front. Pharmacol."},{"issue":"3","key":"e_1_3_3_7_2","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/joim.13169","article-title":"Systemic amyloidosis from A (AA) to T (ATTR): a review","volume":"289","author":"Muchtar E","year":"2021","unstructured":"Muchtar E, Dispenzieri A, Magen H Systemic amyloidosis from A (AA) to T (ATTR): a review. J. Intern. Med. 289(3), 268\u2013292 (2021).","journal-title":"J. Intern. Med."},{"issue":"2","key":"e_1_3_3_8_2","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s40271-017-0273-5","article-title":"Light chain (AL) amyloidosis: the journey to diagnosis","volume":"11","author":"McCausland KL","year":"2018","unstructured":"McCausland KL, White MK, Guthrie SD Light chain (AL) amyloidosis: the journey to diagnosis. Patient 11(2), 207\u2013216 (2018).","journal-title":"Patient"},{"issue":"15","key":"e_1_3_3_9_2","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1182\/blood-2016-11-751628","article-title":"Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death","volume":"129","author":"Muchtar E","year":"2017","unstructured":"Muchtar E, Gertz MA, Kumar SK Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death. Blood 129(15), 2111\u20132119 (2017).","journal-title":"Blood"},{"issue":"25","key":"e_1_3_3_10_2","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1200\/JCO.2013.50.0892","article-title":"Increased serum free light chains precede the presentation of immunoglobulin light chain amyloidosis","volume":"32","author":"Weiss BM","year":"2014","unstructured":"Weiss BM, Hebreo J, Cordaro DV Increased serum free light chains precede the presentation of immunoglobulin light chain amyloidosis. J. Clin. Oncol. 32(25), 2699\u20132704 (2014).","journal-title":"J. Clin. Oncol."},{"issue":"36","key":"e_1_3_3_11_2","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1200\/JCO.2011.37.7614","article-title":"New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes","volume":"30","author":"Palladini G","year":"2012","unstructured":"Palladini G, Dispenzieri A, Gertz MA New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J. Clin. Oncol. 30(36), 4541\u20134549 (2012).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_3_12_2","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1182\/blood-2020-140708","article-title":"First glimpse on real-world efficacy outcomes for 2000 patients with systemic light chain amyloidosis in Europe: a retrospective observational multicenter study by the European Myeloma Network","volume":"136","author":"Palladini G","year":"2020","unstructured":"Palladini G, Sch\u00f6nland S, Merlini G First glimpse on real-world efficacy outcomes for 2000 patients with systemic light chain amyloidosis in Europe: a retrospective observational multicenter study by the European Myeloma Network. Blood 136, 50\u201351 (2020).","journal-title":"Blood"},{"issue":"1","key":"e_1_3_3_13_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13023-016-0564-2","article-title":"The burden of amyloid light chain amyloidosis on health-related quality of life","volume":"12","author":"Bayliss M","year":"2017","unstructured":"Bayliss M, Mccausland KL, Guthrie SD, White MK. The burden of amyloid light chain amyloidosis on health-related quality of life. Orphanet J. Rare Dis. 12(1), 1\u201310 (2017).","journal-title":"Orphanet J. Rare Dis."},{"key":"e_1_3_3_14_2","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1741-7015-12-2","article-title":"Induction therapy with bortezomib and dexamethasone followed by autologous stem cell transplantation versus autologous stem cell transplantation alone in the treatment of renal AL amyloidosis: a randomized controlled trial","volume":"12","author":"Huang X","year":"2014","unstructured":"Huang X, Wang Q, Chen W Induction therapy with bortezomib and dexamethasone followed by autologous stem cell transplantation versus autologous stem cell transplantation alone in the treatment of renal AL amyloidosis: a randomized controlled trial. BMC Med. 12, 2 (2014).","journal-title":"BMC Med."},{"issue":"1","key":"e_1_3_3_15_2","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1182\/blood-2019-122087","article-title":"Doxycycline combined with bortezomib-cyclophosphamide-dexamethasone chemotherapy for newly diagnosed patients with Mayo 2004 stage II\u2013III light-chain amyloidosis: a randomized controlled multicenter study","volume":"134","author":"Shen K","year":"2019","unstructured":"Shen K, Dong Y, Fu W Doxycycline combined with bortezomib-cyclophosphamide-dexamethasone chemotherapy for newly diagnosed patients with Mayo 2004 stage II\u2013III light-chain amyloidosis: a randomized controlled multicenter study. Blood 134(Suppl. 1), 1870 (2019).","journal-title":"Blood"},{"issue":"28","key":"e_1_3_3_16_2","doi-asserted-by":"crossref","first-page":"3252","DOI":"10.1200\/JCO.20.01285","article-title":"Bortezomib, melphalan, and dexamethasone for light-chain amyloidosis","volume":"38","author":"Kastritis E","year":"2020","unstructured":"Kastritis E, Leleu X, Arnulf B Bortezomib, melphalan, and dexamethasone for light-chain amyloidosis. J. Clin. Oncol. 38(28), 3252\u20133260 (2020).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_3_17_2","volume-title":"25th Congress of the European Hematology Association.","author":"Kastritis E","year":"2020","unstructured":"Kastritis E, Palladini G, Minnema M Subcutaneous daratumumab + cyclophosphamide, bortezomib, and dexamethasone (CyBorD) in patients with newly diagnosed light Chain (AL) amyloidosis: primary results from the phase 3 ANDROMEDA study. 25th Congress of the European Hematology Association. Virtual (11-21 June 2020)."},{"key":"e_1_3_3_18_2","unstructured":"Amyloidosis Research Consortium. Guidance for industry: AL amyloidosis \u2013 developing drugs for treatment (2016). www.arci.org\/wp-content\/uploads\/2018\/04\/Guidance-for-Industry-AL-Amyloidosis-Developing-Drugs-for-Treatment-12_16.pdf"},{"issue":"11","key":"e_1_3_3_19_2","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1038\/leu.2012.100","article-title":"Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis","volume":"26","author":"Comenzo RL","year":"2012","unstructured":"Comenzo RL, Reece D, Palladini G Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis. Leukemia 26(11), 2317\u20132325 (2012).","journal-title":"Leukemia"},{"key":"e_1_3_3_20_2","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1182\/blood-2018-99-116688","article-title":"Achieving a difference in involved and uninvolved light chains (dFLC) of less than 10 mg\/l is the new goal of therapy in systemic AL amyloidosis: analysis of 916 patients treated upfront with bortezomib-based therapy","volume":"132","author":"Manwani R","year":"2018","unstructured":"Manwani R, Sharpley F, Mahmood S Achieving a difference in involved and uninvolved light chains (dFLC) of less than 10 mg\/l is the new goal of therapy in systemic AL amyloidosis: analysis of 916 patients treated upfront with bortezomib-based therapy. Blood 132, 3262 (2018).","journal-title":"Blood"},{"issue":"2","key":"e_1_3_3_21_2","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/s41375-018-0258-y","article-title":"Optimizing deep response assessment for AL amyloidosis using involved free light chain level at end of therapy: failure of the serum free light chain ratio","volume":"33","author":"Muchtar E","year":"2019","unstructured":"Muchtar E, Dispenzieri A, Leung N Optimizing deep response assessment for AL amyloidosis using involved free light chain level at end of therapy: failure of the serum free light chain ratio. Leukemia 33(2), 527\u2013531 (2019).","journal-title":"Leukemia"},{"issue":"5","key":"e_1_3_3_22_2","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1038\/s41375-019-0664-9","article-title":"Revisiting complete response in light chain amyloidosis","volume":"34","author":"Sidana S","year":"2020","unstructured":"Sidana S, Dispenzieri A, Murray DL Revisiting complete response in light chain amyloidosis. Leukemia 34(5), 1472\u20131475 (2020).","journal-title":"Leukemia"},{"issue":"1","key":"e_1_3_3_23_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/13506129.2020.1868810","article-title":"Clarification on the definition of complete haematologic response in light-chain (AL) amyloidosis","volume":"28","author":"Palladini G","year":"2021","unstructured":"Palladini G, Schonland SO, Sanchorawala V Clarification on the definition of complete haematologic response in light-chain (AL) amyloidosis. Amyloid 28(1), 1\u20132 (2021).","journal-title":"Amyloid"},{"issue":"2","key":"e_1_3_3_24_2","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3324\/haematol.2013.087619","article-title":"Update on treatment of light chain amyloidosis","volume":"99","author":"Mahmood S","year":"2014","unstructured":"Mahmood S, Palladini G, Sanchorawala V, Wechalekar A. Update on treatment of light chain amyloidosis. Haematologica 99(2), 209\u2013221 (2014).","journal-title":"Haematologica"},{"issue":"7","key":"e_1_3_3_25_2","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1002\/ajh.25819","article-title":"Immunoglobulin light chain amyloidosis: 2020 update on diagnosis, prognosis, and treatment","volume":"95","author":"Gertz MA","year":"2020","unstructured":"Gertz MA. Immunoglobulin light chain amyloidosis: 2020 update on diagnosis, prognosis, and treatment. Am. J. Hematol. 95(7), 848\u2013860 (2020).","journal-title":"Am. J. Hematol."},{"issue":"6","key":"e_1_3_3_26_2","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.2215\/CJN.02740806","article-title":"Light-chain (AL) amyloidosis: diagnosis and treatment","volume":"1","author":"Sanchorawala V","year":"2006","unstructured":"Sanchorawala V. Light-chain (AL) amyloidosis: diagnosis and treatment. Clin. J. Am. Soc. Nephrol. 1(6), 1331\u20131341 (2006).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"e_1_3_3_27_2","volume-title":"21st congress of the European Hematology Association.","author":"Schutz N","year":"2016","unstructured":"Schutz N, Nucifora E, Fantl D AL amyloidosis: real world evidence from Argentina. Presented at: 21st congress of the European Hematology Association. Copenhagen, Denmark (9-12 June 2016)."},{"key":"e_1_3_3_28_2","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1182\/blood-2020-140405","article-title":"Real-world treatment patterns in patients with light chain (AL) amyloidosis: analysis of the Optum US electronic health records (EHR) and commercial claims database","volume":"136","author":"Dispenzieri A","year":"2020","unstructured":"Dispenzieri A, Zonder J, Hoffman J Real-world treatment patterns in patients with light chain (AL) amyloidosis: analysis of the Optum US electronic health records (EHR) and commercial claims database. Blood 136, 4\u20135 (2020).","journal-title":"Blood"},{"issue":"4","key":"e_1_3_3_29_2","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/ajh.20381","article-title":"Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18\u201322 April 2004","volume":"79","author":"Gertz MA","year":"2005","unstructured":"Gertz MA, Comenzo R, Falk RH Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18\u201322 April 2004. Am. J. Hematol. 79(4), 319\u2013328 (2005).","journal-title":"Am. J. Hematol."},{"issue":"7052","key":"e_1_3_3_30_2","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1136\/bmj.313.7052.275","article-title":"Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party","volume":"313","author":"Drummond MF","year":"1996","unstructured":"Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. BMJ 313(7052), 275\u2013283 (1996).","journal-title":"BMJ"},{"key":"e_1_3_3_31_2","unstructured":"National Institute for Health and Care Excellence. Single technology appraisal: user guide for company evidence submission template. www.nice.org.uk\/process\/pmg24\/chapter\/clinical-effectiveness#quality-assessment-of-the-relevant-clinical-effectiveness-evidence"},{"key":"e_1_3_3_32_2","unstructured":"National Institute for Health and Care Excellence: Decision Support Unit. Technical Support Document 9: the identification review and synthesis of health state utility values from the literature. http:\/\/nicedsu.org.uk\/wp-content\/uploads\/2016\/03\/TSD9-HSUV-values_FINAL.pdf"},{"issue":"4","key":"e_1_3_3_33_2","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.jval.2013.02.017","article-title":"Systematic searching and selection of health state utility values from the literature","volume":"16","author":"Papaioannou D","year":"2013","unstructured":"Papaioannou D, Brazier J, Paisley S. Systematic searching and selection of health state utility values from the literature. Value Health 16(4), 686\u2013695 (2013).","journal-title":"Value Health"},{"key":"e_1_3_3_34_2","unstructured":"Ottawa Hospital Research Institute. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp"},{"issue":"3","key":"e_1_3_3_35_2","first-page":"e123","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement","volume":"3","author":"Moher D","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. Open Med. 3(3), e123\u2013130 (2009).","journal-title":"Open Med."},{"key":"e_1_3_3_36_2","unstructured":"Clinicaltrials.gov. Melphalan and dexamethasone with or without bortezomib in treating patients with previously untreated systemic light-chain amyloidosis. https:\/\/clinicaltrials.gov\/show\/NCT01078454 (2010)."},{"issue":"1","key":"e_1_3_3_37_2","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1182\/blood.2019004460","article-title":"Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA","volume":"136","author":"Palladini G","year":"2020","unstructured":"Palladini G, Kastritis E, Maurer MS Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA. Blood 136(1), 71\u201380 (2020).","journal-title":"Blood"},{"issue":"1","key":"e_1_3_3_38_2","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1182\/blood-2020-140514","article-title":"Rapid and deep hematologic responses are associated with improved major organ deterioration progression-free survival in newly diagnosed AL amyloidosis: results from andromeda","volume":"136","author":"Wechalekar A","year":"2020","unstructured":"Wechalekar A, Palladini G, Merlini G Rapid and deep hematologic responses are associated with improved major organ deterioration progression-free survival in newly diagnosed AL amyloidosis: results from andromeda. Blood 136(Suppl. 1), 6\u20137 (2020).","journal-title":"Blood"},{"key":"e_1_3_3_39_2","volume-title":"62nd ASH Annual Meeting Exposition.","author":"Suzuki K","year":"2020","unstructured":"Suzuki K, Wechalekar A, Kim K Subcutaneous daratumumab (DARA SC) + bortezomib, cyclophosphamide, and dexamethasone (VCd) in Asian patients with newly diagnosed light chain (AL) amyloidosis: subgroup analysis from the phase 3 ANDROMEDA study. Presented at: 62nd ASH Annual Meeting Exposition. Virtual Meeting (5-8 December 2020)."},{"issue":"1","key":"e_1_3_3_40_2","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1182\/blood-2020-139438","article-title":"Health-related quality of life in patients with AL amyloidosis treated with daratumumab, bortezomib, cyclophosphamide, and dexamethasone: results from the phase 3 ANDROMEDA study","volume":"136","author":"Sanchorawala V","year":"2020","unstructured":"Sanchorawala V, Palladini G, Minnema M Health-related quality of life in patients with AL amyloidosis treated with daratumumab, bortezomib, cyclophosphamide, and dexamethasone: results from the phase 3 ANDROMEDA study. Blood 136(Suppl. 1), 37\u201340 (2020).","journal-title":"Blood"},{"issue":"1","key":"e_1_3_3_41_2","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1182\/blood-2020-139754","article-title":"Outcomes by cardiac stage in newly diagnosed AL amyloidosis: results from ANDROMEDA","volume":"136","author":"Minnema M","year":"2020","unstructured":"Minnema M, Dispenzieri A, Merlini G Outcomes by cardiac stage in newly diagnosed AL amyloidosis: results from ANDROMEDA. Blood 136(Suppl. 1), 44\u201345 (2020).","journal-title":"Blood"},{"key":"e_1_3_3_42_2","volume-title":"62nd ASH Annual Meeting and Exposition.","author":"Comenzo R","year":"2020","unstructured":"Comenzo R, Kastritis E, Palladini G Reduction in absolute involved free light chain and difference between involved and uninvolved free light chain is associated with prolonged major organ deterioration progression-free survival in patients with newly diagnosed AL amyloidosis receiving bortezomib, cyclophosphamide, and dexamethasone with or without daratumumab: results from ANDROMEDA. Presented at: 62nd ASH Annual Meeting and Exposition. Virtual Meeting (5-8 December 2020)."},{"issue":"1","key":"e_1_3_3_43_2","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1182\/blood-2019-128208","article-title":"Clinical impact of an early response and of early initiation of salvage therapy in patients with systemic light chain (AL) amyloidosis","volume":"134","author":"Kastritis E","year":"2019","unstructured":"Kastritis E, Gavriatopoulou M, Roussou M Clinical impact of an early response and of early initiation of salvage therapy in patients with systemic light chain (AL) amyloidosis. Blood 134( Suppl. 1), 1894 (2019).","journal-title":"Blood"},{"issue":"3","key":"e_1_3_3_44_2","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1365-2141.2008.07327.x","article-title":"Predictors of survival in patients with systemic light-chain amyloidosis and cardiac involvement initially ineligible for stem cell transplantation and treated with oral melphalan and dexamethasone","volume":"143","author":"Lebovic D","year":"2008","unstructured":"Lebovic D, Hoffman J, Levine BM Predictors of survival in patients with systemic light-chain amyloidosis and cardiac involvement initially ineligible for stem cell transplantation and treated with oral melphalan and dexamethasone. Br. J. Haematol. 143(3), 369\u2013373 (2008).","journal-title":"Br. J. Haematol."},{"issue":"1","key":"e_1_3_3_45_2","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1182\/blood-2019-130364","article-title":"Sequential therapy with cyclophosphamide, bortezomib and dexamethasone followed by autologous stem cell transplant is safe and highly effective in AL amyloidosis","volume":"134","author":"Basset M","year":"2019","unstructured":"Basset M, Milani P, Foli A Sequential therapy with cyclophosphamide, bortezomib and dexamethasone followed by autologous stem cell transplant is safe and highly effective in AL amyloidosis. Blood 134(Suppl. 1), 3312 (2019).","journal-title":"Blood"},{"issue":"11","key":"e_1_3_3_46_2","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.3324\/haematol.2018.213900","article-title":"Bortezomib-based induction followed by stem cell transplantation in light chain amyloidosis: results of the multicenter HOVON 104 trial","volume":"104","author":"Minnema MC","year":"2019","unstructured":"Minnema MC, Nasserinejad K, Hazenberg B Bortezomib-based induction followed by stem cell transplantation in light chain amyloidosis: results of the multicenter HOVON 104 trial. Haematologica 104(11), 2274\u20132282 (2019).","journal-title":"Haematologica"},{"issue":"7","key":"e_1_3_3_47_2","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/bmt.2015.73","article-title":"Bortezomib-based induction for transplant ineligible AL amyloidosis and feasibility of later transplantation","volume":"50","author":"Cornell RF","year":"2015","unstructured":"Cornell RF, Zhong X, Arce-Lara C Bortezomib-based induction for transplant ineligible AL amyloidosis and feasibility of later transplantation. Bone Marrow Transplant. 50(7), 914\u2013917 (2015).","journal-title":"Bone Marrow Transplant."},{"issue":"8","key":"e_1_3_3_48_2","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/j.bbmt.2015.04.001","article-title":"Induction therapy with bortezomib followed by bortezomib-high dose melphalan and stem cell transplantation for light chain amyloidosis: results of a prospective clinical trial","volume":"21","author":"Sanchorawala V","year":"2015","unstructured":"Sanchorawala V, Brauneis D, Shelton AC Induction therapy with bortezomib followed by bortezomib-high dose melphalan and stem cell transplantation for light chain amyloidosis: results of a prospective clinical trial. Biol. Blood Marrow Transplant. 21(8), 1445\u20131451 (2015).","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"7","key":"e_1_3_3_49_2","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.clml.2018.04.006","article-title":"Treatment with bortezomib-based therapy, followed by autologous stem cell transplantation, improves outcomes in light chain amyloidosis: a retrospective study","volume":"18","author":"Jain T","year":"2018","unstructured":"Jain T, Kosiorek HE, Kung ST Treatment with bortezomib-based therapy, followed by autologous stem cell transplantation, improves outcomes in light chain amyloidosis: a retrospective study. Clin. Lymphoma Myeloma Leuk. 18(7), 486\u2013492.e481 (2018).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"17","key":"e_1_3_3_50_2","doi-asserted-by":"crossref","first-page":"4175","DOI":"10.1182\/bloodadvances.2020002219","article-title":"Sequential response-driven bortezomib-based therapy followed by autologous stem cell transplant in AL amyloidosis","volume":"4","author":"Basset M","year":"2020","unstructured":"Basset M, Milani P, Nuvolone M Sequential response-driven bortezomib-based therapy followed by autologous stem cell transplant in AL amyloidosis. Blood Adv. 4(17), 4175\u20134179 (2020).","journal-title":"Blood Adv."},{"issue":"1","key":"e_1_3_3_51_2","first-page":"486","article-title":"Autologous stem cell transplant after induction therapy improves outcome in initially ineligible patients with systemic immunoglobulin light chain amyloidosis","volume":"4","author":"Cappuccio I","year":"2020","unstructured":"Cappuccio I, Pugliese N, De Novellis D Autologous stem cell transplant after induction therapy improves outcome in initially ineligible patients with systemic immunoglobulin light chain amyloidosis. HemaSphere 4(Suppl. 1), 486\u2013487 (2020).","journal-title":"HemaSphere"},{"issue":"2","key":"e_1_3_3_52_2","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1080\/13506129.2020.1835635","article-title":"The role of induction therapy before autologous stem cell transplantation in low disease burden AL amyloidosis patients","volume":"28","author":"Huang X","year":"2021","unstructured":"Huang X, Ren G, Chen W The role of induction therapy before autologous stem cell transplantation in low disease burden AL amyloidosis patients. Amyloid 28(2), 75\u201383 (2021).","journal-title":"Amyloid"},{"issue":"4","key":"e_1_3_3_53_2","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/s41409-020-01136-2","article-title":"Depth of response prior to autologous stem cell transplantation predicts survival in light chain amyloidosis","volume":"56","author":"Vaxman I","year":"2021","unstructured":"Vaxman I, Sidiqi MH, Al Saleh AS Depth of response prior to autologous stem cell transplantation predicts survival in light chain amyloidosis. Bone Marrow Transplant. 56(4), 928\u2013935 (2021).","journal-title":"Bone Marrow Transplant."},{"issue":"10","key":"e_1_3_3_54_2","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/j.nut.2015.04.011","article-title":"Nutritional counseling improves quality of life and preserves body weight in systemic immunoglobulin light-chain (AL) amyloidosis","volume":"31","author":"Caccialanza R","year":"2015","unstructured":"Caccialanza R, Palladini G, Cereda E Nutritional counseling improves quality of life and preserves body weight in systemic immunoglobulin light-chain (AL) amyloidosis. Nutrition 31(10), 1228\u20131234 (2015).","journal-title":"Nutrition"},{"issue":"3","key":"e_1_3_3_55_2","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00277-011-1309-x","article-title":"Nutritional status independently affects quality of life of patients with systemic immunoglobulin light-chain (AL) amyloidosis","volume":"91","author":"Caccialanza R","year":"2012","unstructured":"Caccialanza R, Palladini G, Klersy C Nutritional status independently affects quality of life of patients with systemic immunoglobulin light-chain (AL) amyloidosis. Ann. Hematol. 91(3), 399\u2013406 (2012).","journal-title":"Ann. Hematol."},{"issue":"1","key":"e_1_3_3_56_2","doi-asserted-by":"crossref","first-page":"136","DOI":"10.3324\/haematol.2012.070359","article-title":"A prospective study of nutritional status in immunoglobulin light chain amyloidosis","volume":"98","author":"Sattianayagam PT","year":"2013","unstructured":"Sattianayagam PT, Lane T, Fox Z A prospective study of nutritional status in immunoglobulin light chain amyloidosis. Haematologica 98(1), 136\u2013140 (2013).","journal-title":"Haematologica"},{"issue":"3","key":"e_1_3_3_57_2","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/bjh.14889","article-title":"A longitudinal evaluation of health-related quality of life in patients with AL amyloidosis: associations with health outcomes over time","volume":"179","author":"Sanchorawala V","year":"2017","unstructured":"Sanchorawala V, Mccausland KL, White MK A longitudinal evaluation of health-related quality of life in patients with AL amyloidosis: associations with health outcomes over time. Br. J. Haematol. 179(3), 461\u2013470 (2017).","journal-title":"Br. J. Haematol."},{"issue":"6","key":"e_1_3_3_58_2","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1182\/blood-2004-01-0089","article-title":"Improvement in quality of life of patients with AL amyloidosis treated with high-dose melphalan and autologous stem cell transplantation","volume":"104","author":"Seldin DC","year":"2004","unstructured":"Seldin DC, Anderson JJ, Sanchorawala V Improvement in quality of life of patients with AL amyloidosis treated with high-dose melphalan and autologous stem cell transplantation. Blood 104(6), 1888\u20131893 (2004).","journal-title":"Blood"},{"issue":"2","key":"e_1_3_3_59_2","doi-asserted-by":"crossref","first-page":"S388","DOI":"10.1016\/j.jval.2019.04.1896","article-title":"RO2 Assessing the relationship between lifelong value and pricing for orphan drugs in ultra-rare diseases","volume":"22","author":"Dabbous O","year":"2019","unstructured":"Dabbous O, Zhou ZY, Tang C, Harvey M, Wu EQ, Arjunji R. RO2 Assessing the relationship between lifelong value and pricing for orphan drugs in ultra-rare diseases. Value Health 22(Suppl. 2), S388 (2019).","journal-title":"Value Health"},{"issue":"2","key":"e_1_3_3_60_2","first-page":"297","article-title":"Untangling hospitalizations in systemic amyloidosis: patient characteristics, economic cost and clinical outcomes","volume":"2","author":"Quock TP","year":"2018","unstructured":"Quock TP, Yan T, Tieu R, Souza AD, Broder M. Untangling hospitalizations in systemic amyloidosis: patient characteristics, economic cost and clinical outcomes. HemaSphere 2(Suppl. 2), 297 (2018).","journal-title":"HemaSphere"},{"key":"e_1_3_3_61_2","unstructured":"National Institute for Health Research. Ixazomib in combination with oral dexamethasone for relapsed or refractory systemic light chain (AL) amyloidosis. (2014). www.io.nihr.ac.uk\/wp-content\/uploads\/migrated\/2585.05573742.Ixazomibcitrate_amyloidosis_March2014.pdf"},{"key":"e_1_3_3_62_2","first-page":"S334","article-title":"A proactive approach to plerixafor use and subsequent apheresis can reduce failed autologous PBSC mobilization rates to virtually zero after two mobilization attempts: a single-centre series of 40 consecutive PBSC mobilization episodes using plerixafor","volume":"46","author":"Douglas K","year":"2011","unstructured":"Douglas K, Sinclair J, Mcquaker G A proactive approach to plerixafor use and subsequent apheresis can reduce failed autologous PBSC mobilization rates to virtually zero after two mobilization attempts: a single-centre series of 40 consecutive PBSC mobilization episodes using plerixafor. Bone Marrow Transplant. 46, S334 (2011).","journal-title":"Bone Marrow Transplant."},{"issue":"3","key":"e_1_3_3_63_2","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s41669-019-0122-7","article-title":"Associations between health-related quality of life and self-reported emergency room department visits and inpatient hospitalizations: insights from a secondary data analysis of patients with light-chain (AL) amyloidosis","volume":"3","author":"McCausland KL","year":"2019","unstructured":"McCausland KL, Rizio AA, White MK, Bayliss MS, Quock TP. Associations between health-related quality of life and self-reported emergency room department visits and inpatient hospitalizations: insights from a secondary data analysis of patients with light-chain (AL) amyloidosis. Pharmacoecon. Open 3(3), 367\u2013375 (2019).","journal-title":"Pharmacoecon. Open"},{"issue":"3","key":"e_1_3_3_64_2","doi-asserted-by":"crossref","first-page":"S311","DOI":"10.1016\/j.bbmt.2017.12.320","article-title":"Healthcare resource utilization for patients undergoing autologous stem cell transplantation: identification of cost drivers","volume":"24","author":"Blanco M","year":"2018","unstructured":"Blanco M, Gordillo CA, Mapara MY, Satwani P, Reshef R. Healthcare resource utilization for patients undergoing autologous stem cell transplantation: identification of cost drivers. Biol. Blood Marrow Transplant. 24(3 Suppl. 1), S311 (2018).","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"1","key":"e_1_3_3_65_2","first-page":"4659","article-title":"Healthcare utilization and costs in commercially insured patients with AL amyloidosis","volume":"130","author":"Quock TP","year":"2017","unstructured":"Quock TP, Yan JT, Chang E, Guthrie SD, Broder MS. Healthcare utilization and costs in commercially insured patients with AL amyloidosis. Blood 130(Suppl. 1), 4659 (2017).","journal-title":"Blood"},{"issue":"1","key":"e_1_3_3_66_2","first-page":"505","article-title":"Economic and clinical outcomes of hospital care in patients with cardiac amyloidosis","volume":"39","author":"Quock TP","year":"2018","unstructured":"Quock TP, Yan T, Tieu R, Souza AD, Broder M. Economic and clinical outcomes of hospital care in patients with cardiac amyloidosis. Eur. Heart J. 39(Suppl. 1), 505 (2018).","journal-title":"Eur. Heart J."},{"issue":"3","key":"e_1_3_3_67_2","doi-asserted-by":"crossref","first-page":"S462","DOI":"10.1016\/j.jval.2018.09.2727","article-title":"Understanding patterns of 30-day readmission in patients with cardiac amyloidosis","volume":"21","author":"Quock TP","year":"2018","unstructured":"Quock TP, Yan T, Tieu RS, Souza AD, Broder MS. Understanding patterns of 30-day readmission in patients with cardiac amyloidosis. Value Health 21(Suppl. 3), S462 (2018).","journal-title":"Value Health"},{"issue":"8","key":"e_1_3_3_68_2","doi-asserted-by":"crossref","first-page":"S124","DOI":"10.1016\/j.cardfail.2017.07.365","article-title":"Trends of cardiac transplantation in cardiac amyloidosis in the United States from 2008\u20132014","volume":"23","author":"Taduru SS","year":"2017","unstructured":"Taduru SS, Roy SD, Taneja A Trends of cardiac transplantation in cardiac amyloidosis in the United States from 2008\u20132014. J. Card. Fail. 23(8 Suppl. 1), S124 (2017).","journal-title":"J. Card. Fail."},{"issue":"4","key":"e_1_3_3_69_2","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/bmt.2014.318","article-title":"Superior efficacy but higher cost of plerixafor and abbreviated-course G-CSF for mobilizing hematopoietic progenitor cells (HPC) in AL amyloidosis","volume":"50","author":"Dhakal B","year":"2015","unstructured":"Dhakal B, Souza AD, Arce-Lara C Superior efficacy but higher cost of plerixafor and abbreviated-course G-CSF for mobilizing hematopoietic progenitor cells (HPC) in AL amyloidosis. Bone Marrow Transplant. 50(4), 610\u2013612 (2015).","journal-title":"Bone Marrow Transplant."},{"issue":"1","key":"e_1_3_3_70_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/13506129.2017.1411796","article-title":"Treatment patterns and health care resource utilization among patients with relapsed\/refractory systemic light chain amyloidosis","volume":"25","author":"Hari P","year":"2018","unstructured":"Hari P, Lin HM, Asche CV Treatment patterns and health care resource utilization among patients with relapsed\/refractory systemic light chain amyloidosis. Amyloid 25(1), 1\u20137 (2018).","journal-title":"Amyloid"},{"key":"e_1_3_3_71_2","doi-asserted-by":"publisher","DOI":"10.2217\/cer-2018-0062"},{"key":"e_1_3_3_72_2","doi-asserted-by":"publisher","DOI":"10.2217\/cer-2017-0100"},{"key":"e_1_3_3_73_2","doi-asserted-by":"crossref","first-page":"431","DOI":"10.2147\/CEOR.S207127","article-title":"Untangling the clinical and economic burden of hospitalization for cardiac amyloidosis in the United States","volume":"11","author":"Quock TP","year":"2019","unstructured":"Quock TP, Yan T, Tieu R, Souza AD, Broder MS. Untangling the clinical and economic burden of hospitalization for cardiac amyloidosis in the United States. Clinicoecon. Outcomes Res. 11, 431\u2013439 (2019).","journal-title":"Clinicoecon. Outcomes Res."},{"issue":"11","key":"e_1_3_3_74_2","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/S0735-1097(20)31684-3","article-title":"An analysis of patients hospitalized with cardiac amyloidosis and heart failure in the United States: insight from the National Inpatient Sample","volume":"75","author":"Dastmalchi LN","year":"2020","unstructured":"Dastmalchi LN, Atanda AC, Krepp J. An analysis of patients hospitalized with cardiac amyloidosis and heart failure in the United States: insight from the National Inpatient Sample. J. Am. Coll. Cardiol. 75(11), 1057 (2020).","journal-title":"J. Am. Coll. Cardiol."},{"issue":"4","key":"e_1_3_3_75_2","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/joa3.12376","article-title":"Trends, burden, and impact of arrhythmia on cardiac amyloid patients: a 16-year nationwide study from 1999 to 2014","volume":"36","author":"Isath A","year":"2020","unstructured":"Isath A, Correa A, Siroky GP Trends, burden, and impact of arrhythmia on cardiac amyloid patients: a 16-year nationwide study from 1999 to 2014. J. Arrhythm. 36(4), 727\u2013734 (2020).","journal-title":"J. Arrhythm."},{"issue":"11","key":"e_1_3_3_76_2","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S0735-1097(20)30998-0","article-title":"Trends, predictors and impact of arrhythmias in cardiac amyloidosis: a 16-year analysis (1999\u20132014)","volume":"75","author":"Isath A","year":"2020","unstructured":"Isath A, Padmanabhan D, Perimbeti S Trends, predictors and impact of arrhythmias in cardiac amyloidosis: a 16-year analysis (1999\u20132014). J. Am. Coll. Cardiol. 75(11), 371 (2020).","journal-title":"J. Am. Coll. Cardiol."},{"issue":"11","key":"e_1_3_3_77_2","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/S0735-1097(20)31075-5","article-title":"Trends and impact of implantable cardioverter defibrillator implantations in patients with cardiac amyloidosis: a 16-year analysis","volume":"75","author":"Isath A","year":"2020","unstructured":"Isath A, Perimbeti S, Correa A Trends and impact of implantable cardioverter defibrillator implantations in patients with cardiac amyloidosis: a 16-year analysis. J. Am. Coll. Cardiol. 75(11), 448 (2020).","journal-title":"J. Am. Coll. Cardiol."},{"key":"e_1_3_3_78_2","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.amjcard.2020.12.024","article-title":"Impact of arrhythmias on hospitalizations in patients with cardiac amyloidosis","volume":"143","author":"Thakkar S","year":"2020","unstructured":"Thakkar S, Patel HP, Chowdhury M Impact of arrhythmias on hospitalizations in patients with cardiac amyloidosis. Am. J. Cardiol. 143, 125\u2013130 (2020).","journal-title":"Am. J. Cardiol."},{"issue":"6","key":"e_1_3_3_79_2","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1080\/03007995.2017.1297930","article-title":"Disease burden of systemic light-chain amyloidosis: a systematic literature review","volume":"33","author":"Lin HM","year":"2017","unstructured":"Lin HM, Gao X, Cooke CE Disease burden of systemic light-chain amyloidosis: a systematic literature review. Curr. Med. Res. Opin. 33(6), 1017\u20131031 (2017).","journal-title":"Curr. Med. Res. Opin."},{"issue":"6","key":"e_1_3_3_80_2","doi-asserted-by":"crossref","first-page":"e005407","DOI":"10.1161\/CIRCHEARTFAILURE.118.005407","article-title":"Epidemiology of cardiac amyloidosis-associated heart failure hospitalizations among fee-for-service Medicare beneficiaries in the United States","volume":"12","author":"Gilstrap LG","year":"2019","unstructured":"Gilstrap LG, Dominici F, Wang Y Epidemiology of cardiac amyloidosis-associated heart failure hospitalizations among fee-for-service Medicare beneficiaries in the United States. Circ. Heart Fail. 12(6), e005407 (2019).","journal-title":"Circ. Heart Fail."},{"issue":"10","key":"e_1_3_3_81_2","doi-asserted-by":"crossref","first-page":"S75","DOI":"10.1016\/j.cjca.2020.07.150","article-title":"The incidence rates of cardiac amyloidosis over two decades in Alberta, Canada","volume":"36","author":"Sepehrvand N","year":"2020","unstructured":"Sepehrvand N, Youngson E, Fine N The incidence rates of cardiac amyloidosis over two decades in Alberta, Canada. Can. J. Cardiol. 36(Suppl. 10), S75\u2013S76 (2020).","journal-title":"Can. J. Cardiol."},{"key":"e_1_3_3_82_2","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ahj.2020.12.009","article-title":"Management of heart failure in cardiac amyloidosis using an ambulatory diuresis clinic","volume":"233","author":"Vaishnav J","year":"2020","unstructured":"Vaishnav J, Hubbard A, Chasler JE Management of heart failure in cardiac amyloidosis using an ambulatory diuresis clinic. Am. Heart J. 233, 122\u2013131 (2020).","journal-title":"Am. Heart J."},{"issue":"1","key":"e_1_3_3_83_2","first-page":"97","article-title":"Safety of delivery of bortezomib to patients with cardiac AL amyloidosis: the impact of cardiac monitoring","volume":"185","author":"Attwood C","year":"2019","unstructured":"Attwood C, Sado D, Rice C Safety of delivery of bortezomib to patients with cardiac AL amyloidosis: the impact of cardiac monitoring. Br. J. Haematol. 185(Suppl. 1), 97\u201398 (2019).","journal-title":"Br. J. Haematol."},{"issue":"4","key":"e_1_3_3_84_2","doi-asserted-by":"crossref","first-page":"e454","DOI":"10.1097\/HS9.0000000000000454","article-title":"Systemic AL amyloidosis: current approaches to diagnosis and management","volume":"4","author":"Fotiou D","year":"2020","unstructured":"Fotiou D, Dimopoulos MA, Kastritis E. Systemic AL amyloidosis: current approaches to diagnosis and management. Hemasphere 4(4), e454 (2020).","journal-title":"Hemasphere"},{"issue":"5","key":"e_1_3_3_85_2","first-page":"315","article-title":"How we treat systemic light-chain amyloidosis","volume":"13","author":"Chaulagain C","year":"2015","unstructured":"Chaulagain C, Comenzo R. How we treat systemic light-chain amyloidosis. Clin. Adv. Hematol. Oncol. 13(5), 315\u2013324 (2015).","journal-title":"Clin. Adv. Hematol. Oncol."},{"issue":"1","key":"e_1_3_3_86_2","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1056\/NEJMoa2028631","article-title":"Daratumumab-based treatment for immunoglobulin light-chain amyloidosis","volume":"385","author":"Kastritis E","year":"2021","unstructured":"Kastritis E, Palladini G, Minnema MC Daratumumab-based treatment for immunoglobulin light-chain amyloidosis. N. Engl. J. Med. 385(1), 46\u201358 (2021).","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"e_1_3_3_87_2","doi-asserted-by":"crossref","first-page":"e570","DOI":"10.1038\/bcj.2017.47","article-title":"Addition of cyclophosphamide and higher doses of dexamethasone do not improve outcomes of patients with AL amyloidosis treated with bortezomib","volume":"7","author":"Kastritis E","year":"2017","unstructured":"Kastritis E, Gavriatopoulou M, Roussou M Addition of cyclophosphamide and higher doses of dexamethasone do not improve outcomes of patients with AL amyloidosis treated with bortezomib. Blood Cancer J. 7(6), e570 (2017).","journal-title":"Blood Cancer J."},{"issue":"8","key":"e_1_3_3_88_2","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.healun.2016.03.004","article-title":"Analysis of diagnostic and therapeutic strategies in advanced cardiac light-chain amyloidosis","volume":"35","author":"Sayago I","year":"2016","unstructured":"Sayago I, Krsnik I, Gomez-Bueno M Analysis of diagnostic and therapeutic strategies in advanced cardiac light-chain amyloidosis. J. Heart Lung Transplant. 35(8), 995\u20131002 (2016).","journal-title":"J. Heart Lung Transplant."},{"issue":"12","key":"e_1_3_3_89_2","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1007\/s00277-017-3132-5","article-title":"At least partial hematological response after first cycle of treatment predicts organ response and long-term survival for patients with AL amyloidosis receiving bortezomib-based treatment","volume":"96","author":"Shen KN","year":"2017","unstructured":"Shen KN, Feng J, Huang XF At least partial hematological response after first cycle of treatment predicts organ response and long-term survival for patients with AL amyloidosis receiving bortezomib-based treatment. Ann. Hematol. 96(12), 2089\u20132094 (2017).","journal-title":"Ann. Hematol."},{"issue":"10","key":"e_1_3_3_90_2","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1016\/j.clinthera.2013.08.015","article-title":"Bortezomib subcutaneous injection in combination regimens for myeloma or systemic light-chain amyloidosis: a retrospective chart review of response rates and toxicity in newly diagnosed patients","volume":"35","author":"Shah G","year":"2013","unstructured":"Shah G, Kaul E, Fallo S Bortezomib subcutaneous injection in combination regimens for myeloma or systemic light-chain amyloidosis: a retrospective chart review of response rates and toxicity in newly diagnosed patients. Clin. Ther. 35(10), 1614\u20131620 (2013).","journal-title":"Clin. Ther."},{"issue":"6","key":"e_1_3_3_91_2","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1200\/JCO.2009.23.8220","article-title":"Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis","volume":"28","author":"Kastritis E","year":"2010","unstructured":"Kastritis E, Wechalekar AD, Dimopoulos MA Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. J. Clin. Oncol. 28(6), 1031\u20131037 (2010).","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"e_1_3_3_92_2","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1097\/01.HS9.0000566992.77698.56","article-title":"Bortezomib-high dose methylprednisolone offers improved haematological responses and overall survival compared to bortezomib-dexamethasone in systemic light chain amyloidosis","volume":"3","author":"Mahmood AS","year":"2019","unstructured":"Mahmood AS, Sachchithanantham S, Harrison S Bortezomib-high dose methylprednisolone offers improved haematological responses and overall survival compared to bortezomib-dexamethasone in systemic light chain amyloidosis. HemaSphere 3(Suppl. 1), 958 (2019).","journal-title":"HemaSphere"},{"issue":"10","key":"e_1_3_3_93_2","doi-asserted-by":"crossref","first-page":"e308","DOI":"10.1016\/j.clml.2019.09.507","article-title":"Bortezomib, cyclophosphamide, and dexamethasone (CyBorD) as front-line treatment for systemic AL amyloidosis (AL): a real-world experience at a single centre","volume":"19","author":"Chong YS","year":"2019","unstructured":"Chong YS, Hutani F, Ting S, Lasica M, Gibbs S. Bortezomib, cyclophosphamide, and dexamethasone (CyBorD) as front-line treatment for systemic AL amyloidosis (AL): a real-world experience at a single centre. Clin. Lymphoma Myeloma Leuk. 19(Suppl. 10), e308\u2013e309 (2019).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"4","key":"e_1_3_3_94_2","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3109\/13506129.2014.960560","article-title":"Bortezomib, melphalan, and prednisolone combination chemotherapy for newly diagnosed light chain (AL) amyloidosis","volume":"21","author":"Lee JY","year":"2014","unstructured":"Lee JY, Lim SH, Kim SJ Bortezomib, melphalan, and prednisolone combination chemotherapy for newly diagnosed light chain (AL) amyloidosis. Amyloid 21(4), 261\u2013266 (2014).","journal-title":"Amyloid"},{"issue":"5","key":"e_1_3_3_95_2","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/bjh.16122","article-title":"Carfilzomib is an effective upfront treatment in AL amyloidosis patients with peripheral and autonomic neuropathy","volume":"187","author":"Manwani R","year":"2019","unstructured":"Manwani R, Mahmood S, Sachchithanantham S Carfilzomib is an effective upfront treatment in AL amyloidosis patients with peripheral and autonomic neuropathy. Br. J. Haematol. 187(5), 638\u2013641 (2019).","journal-title":"Br. J. Haematol."},{"issue":"6","key":"e_1_3_3_96_2","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/j.clinthera.2018.12.003","article-title":"Cyclophosphamide + thalidomide + dexamethasone versus melphalan + dexamethasone for the treatment of amyloid light-chain amyloidosis with kidney involvement: a retrospective study in Chinese patients","volume":"41","author":"Liu B","year":"2019","unstructured":"Liu B, Wang Y, Bai M Cyclophosphamide + thalidomide + dexamethasone versus melphalan + dexamethasone for the treatment of amyloid light-chain amyloidosis with kidney involvement: a retrospective study in Chinese patients. Clin. Ther. 41(6), 1186\u20131198 (2019).","journal-title":"Clin. Ther."},{"issue":"1","key":"e_1_3_3_97_2","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1182\/blood-2019-124206","article-title":"The effect of cytogenetic abnormalities on organ involvement and survival in patients with AL amyloidosis","volume":"134","author":"Ozga M","year":"2019","unstructured":"Ozga M, Zhao Q, Benson DM The effect of cytogenetic abnormalities on organ involvement and survival in patients with AL amyloidosis. Blood 134(Suppl. 1), 1833 (2019).","journal-title":"Blood"},{"issue":"1","key":"e_1_3_3_98_2","first-page":"44","article-title":"Effect on mortality of combined or sequential chemotherapy in patients with cardiac light-chain amyloidosis","volume":"11","author":"Gilles F","year":"2019","unstructured":"Gilles F, Damy T, Bodez D Effect on mortality of combined or sequential chemotherapy in patients with cardiac light-chain amyloidosis. Arch. Cardiovasc. Dis. Suppl. 11(1), 44\u201345 (2019).","journal-title":"Arch. Cardiovasc. Dis. Suppl."},{"issue":"9","key":"e_1_3_3_99_2","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.3324\/haematol.2014.104109","article-title":"Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naive patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III)","volume":"99","author":"Jaccard A","year":"2014","unstructured":"Jaccard A, Comenzo RL, Hari P Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naive patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III). Haematologica 99(9), 1479\u20131485 (2014).","journal-title":"Haematologica"},{"issue":"25","key":"e_1_3_3_100_2","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1016\/j.jacc.2016.03.593","article-title":"Efficacy of chemotherapy for light-chain amyloidosis in patients presenting with symptomatic heart failure","volume":"67","author":"Sperry BW","year":"2016","unstructured":"Sperry BW, Ikram A, Hachamovitch R Efficacy of chemotherapy for light-chain amyloidosis in patients presenting with symptomatic heart failure. J. Am. Coll. Cardiol. 67(25), 2941\u20132948 (2016).","journal-title":"J. Am. Coll. Cardiol."},{"issue":"5","key":"e_1_3_3_101_2","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1182\/blood-2015-01-620302","article-title":"A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis","volume":"126","author":"Palladini G","year":"2015","unstructured":"Palladini G, Sachchithanantham S, Milani P A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis. Blood 126(5), 612\u2013615 (2015).","journal-title":"Blood"},{"issue":"17","key":"e_1_3_3_102_2","doi-asserted-by":"crossref","first-page":"3420","DOI":"10.1182\/blood-2012-12-473066","article-title":"A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis","volume":"121","author":"Wechalekar AD","year":"2013","unstructured":"Wechalekar AD, Schonland SO, Kastritis E A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood 121(17), 3420\u20133427 (2013).","journal-title":"Blood"},{"issue":"8","key":"e_1_3_3_103_2","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1016\/j.amjcard.2017.07.025","article-title":"Functional cardiac recovery and hematologic response to chemotherapy in patients with light-chain amyloidosis (from the Stanford University Amyloidosis Registry)","volume":"120","author":"Tuzovic M","year":"2017","unstructured":"Tuzovic M, Kobayashi Y, Wheeler M Functional cardiac recovery and hematologic response to chemotherapy in patients with light-chain amyloidosis (from the Stanford University Amyloidosis Registry). Am. J. Cardiol. 120(8), 1381\u20131386 (2017).","journal-title":"Am. J. Cardiol."},{"issue":"1","key":"e_1_3_3_104_2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3109\/13506129.2013.854766","article-title":"Gain of chromosome 1q21 is an independent adverse prognostic factor in light chain amyloidosis patients treated with melphalan\/dexamethasone","volume":"21","author":"Bochtler T","year":"2014","unstructured":"Bochtler T, Hegenbart U, Kunz C Gain of chromosome 1q21 is an independent adverse prognostic factor in light chain amyloidosis patients treated with melphalan\/dexamethasone. Amyloid 21(1), 9\u201317 (2014).","journal-title":"Amyloid"},{"issue":"8","key":"e_1_3_3_105_2","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.3324\/haematol.2016.163246","article-title":"Lenalidomide\/melphalan\/dexamethasone in newly diagnosed patients with immunoglobulin light chain amyloidosis: results of a prospective phase 2 study with long-term follow up","volume":"102","author":"Hegenbart U","year":"2017","unstructured":"Hegenbart U, Bochtler T, Benner A Lenalidomide\/melphalan\/dexamethasone in newly diagnosed patients with immunoglobulin light chain amyloidosis: results of a prospective phase 2 study with long-term follow up. Haematologica 102(8), 1424\u20131431 (2017).","journal-title":"Haematologica"},{"issue":"4","key":"e_1_3_3_106_2","doi-asserted-by":"crossref","first-page":"E60","DOI":"10.1002\/ajh.23936","article-title":"Long-term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies","volume":"90","author":"Kastritis E","year":"2015","unstructured":"Kastritis E, Roussou M, Gavriatopoulou M Long-term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies. Am. J. Hematol. 90(4), E60\u201365 (2015).","journal-title":"Am. J. Hematol."},{"issue":"12","key":"e_1_3_3_107_2","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1038\/leu.2014.218","article-title":"A matched comparison of cyclophosphamide, bortezomib and dexamethasone (CVD) versus risk-adapted cyclophosphamide, thalidomide and dexamethasone (CTD) in AL amyloidosis","volume":"28","author":"Venner CP","year":"2014","unstructured":"Venner CP, Gillmore JD, Sachchithanantham S A matched comparison of cyclophosphamide, bortezomib and dexamethasone (CVD) versus risk-adapted cyclophosphamide, thalidomide and dexamethasone (CTD) in AL amyloidosis. Leukemia 28(12), 2304\u20132310 (2014).","journal-title":"Leukemia"},{"issue":"12","key":"e_1_3_3_108_2","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1038\/leu.2014.227","article-title":"Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case-control study on 174 patients","volume":"28","author":"Palladini G","year":"2014","unstructured":"Palladini G, Milani P, Foli A Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case-control study on 174 patients. Leukemia 28(12), 2311\u20132316 (2014).","journal-title":"Leukemia"},{"issue":"6","key":"e_1_3_3_109_2","doi-asserted-by":"crossref","first-page":"469","DOI":"10.3816\/CLML.2010.n.081","article-title":"Oral cyclic melphalan and dexamethasone for patients with AL amyloidosis","volume":"10","author":"Sanchorawala V","year":"2010","unstructured":"Sanchorawala V, Seldin DC, Berk JL, Sloan JM, Doros G, Skinner M. Oral cyclic melphalan and dexamethasone for patients with AL amyloidosis. Clin. Lymphoma Myeloma Leuk. 10(6), 469\u2013472 (2010).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"4","key":"e_1_3_3_110_2","doi-asserted-by":"crossref","first-page":"743","DOI":"10.3324\/haematol.2013.095463","article-title":"Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach","volume":"99","author":"Palladini G","year":"2014","unstructured":"Palladini G, Milani P, Foli A Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach. Haematologica 99(4), 743\u2013750 (2014).","journal-title":"Haematologica"},{"issue":"1","key":"e_1_3_3_111_2","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1097\/01.HS9.0000567208.36902.c6","article-title":"Outcome of first-line therapy for patients with systemic light-chain amyloidosis: monocentric analysis","volume":"3","author":"Fernandez R","year":"2019","unstructured":"Fernandez R, Soto AS, Cepeda F Outcome of first-line therapy for patients with systemic light-chain amyloidosis: monocentric analysis. HemaSphere 3(Suppl. 1), 979 (2019).","journal-title":"HemaSphere"},{"issue":"10","key":"e_1_3_3_112_2","doi-asserted-by":"crossref","first-page":"e333","DOI":"10.1016\/j.clml.2019.09.548","article-title":"Outcome of first-line therapy in patients with systemic light-chain amyloidosis: a multicentre analysis","volume":"19","author":"Fernandez R","year":"2019","unstructured":"Fernandez R, Soto AS, Muniz S Outcome of first-line therapy in patients with systemic light-chain amyloidosis: a multicentre analysis. Clin. Lymphoma Myeloma Leuk. 19(Suppl. 10), e333\u2013e334 (2019).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"2","key":"e_1_3_3_113_2","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/ejh.12558","article-title":"Outcomes of light-chain amyloidosis patients treated with first-line bortezomib: a collaborative retrospective multicenter assessment","volume":"96","author":"Gatt ME","year":"2016","unstructured":"Gatt ME, Hardan I, Chubar E Outcomes of light-chain amyloidosis patients treated with first-line bortezomib: a collaborative retrospective multicenter assessment. Eur. J. Haematol. 96(2), 136\u2013143 (2016).","journal-title":"Eur. J. Haematol."},{"issue":"6","key":"e_1_3_3_114_2","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1111\/bjh.13500","article-title":"A phase II trial of lenalidomide, dexamethasone and cyclophosphamide for newly diagnosed patients with systemic immunoglobulin light chain amyloidosis","volume":"170","author":"Cibeira MT","year":"2015","unstructured":"Cibeira MT, Oriol A, Lahuerta JJ A phase II trial of lenalidomide, dexamethasone and cyclophosphamide for newly diagnosed patients with systemic immunoglobulin light chain amyloidosis. Br. J. Haematol. 170(6), 804\u2013813 (2015).","journal-title":"Br. J. Haematol."},{"issue":"20","key":"e_1_3_3_115_2","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1182\/bloodadvances.2019000147","article-title":"Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone","volume":"3","author":"Kastritis E","year":"2019","unstructured":"Kastritis E, Dialoupi I, Gavriatopoulou M Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone. Blood Adv. 3(20), 3002\u20133009 (2019).","journal-title":"Blood Adv."},{"issue":"25","key":"e_1_3_3_116_2","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1182\/blood.2019000834","article-title":"A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib","volume":"134","author":"Manwani R","year":"2019","unstructured":"Manwani R, Cohen O, Sharpley F A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib. Blood 134(25), 2271\u20132280 (2019).","journal-title":"Blood"},{"issue":"1","key":"e_1_3_3_117_2","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.clml.2012.09.011","article-title":"Safety and efficacy of triplet regimens in newly diagnosed light chain amyloidosis","volume":"13","author":"Chari A","year":"2013","unstructured":"Chari A, Barley K, Jagannath S, Osman K. Safety and efficacy of triplet regimens in newly diagnosed light chain amyloidosis. Clin. Lymphoma Myeloma Leuk. 13(1), 55\u201361 (2013).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"1","key":"e_1_3_3_118_2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.patbio.2014.10.001","article-title":"Successful treatment of renal light chain (AL) amyloidosis with bortezomib and dexamethasone (VD)","volume":"63","author":"Huang B","year":"2015","unstructured":"Huang B, Li J, Xu X, Zheng D, Zhou Z, Liu J. Successful treatment of renal light chain (AL) amyloidosis with bortezomib and dexamethasone (VD). Pathol. Biol. (Paris) 63(1), 17\u201320 (2015).","journal-title":"Pathol. Biol. (Paris)"},{"issue":"17","key":"e_1_3_3_119_2","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.2169\/internalmedicine.47.0949","article-title":"Therapeutic outcome of cyclic VAD (vincristine, doxorubicin and dexamethasone) therapy in primary systemic AL amyloidosis patients","volume":"47","author":"Tazawa K","year":"2008","unstructured":"Tazawa K, Matsuda M, Yoshida T Therapeutic outcome of cyclic VAD (vincristine, doxorubicin and dexamethasone) therapy in primary systemic AL amyloidosis patients. Intern. Med. 47(17), 1517\u20131522 (2008).","journal-title":"Intern. Med."},{"issue":"12","key":"e_1_3_3_120_2","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1200\/JCO.2014.57.4947","article-title":"Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens","volume":"33","author":"Bochtler T","year":"2015","unstructured":"Bochtler T, Hegenbart U, Kunz C Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens. J. Clin. Oncol. 33(12), 1371\u20131378 (2015).","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"e_1_3_3_121_2","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s00277-008-0600-y","article-title":"Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide","volume":"88","author":"Palladini G","year":"2009","unstructured":"Palladini G, Russo P, Lavatelli F Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide. Ann. Hematol. 88(4), 347\u2013350 (2009).","journal-title":"Ann. Hematol."},{"issue":"1","key":"e_1_3_3_122_2","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1182\/blood-2019-127023","article-title":"Upfront ixazomib plus dexamethasone induce promptly hematological response in patients with light-chain amyloidosis","volume":"134","author":"Wei Z","year":"2019","unstructured":"Wei Z, Zhang Y, Li J, Liu P. Upfront ixazomib plus dexamethasone induce promptly hematological response in patients with light-chain amyloidosis. Blood 134(Suppl. 1), 1908 (2019).","journal-title":"Blood"},{"issue":"1","key":"e_1_3_3_123_2","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3109\/13506129.2016.1138939","article-title":"Bortezomib with dexamethasone as first-line treatment for AL amyloidosis with renal involvement","volume":"23","author":"Huang X","year":"2016","unstructured":"Huang X, Wang Q, Chen W, Ren G, Liu Z. Bortezomib with dexamethasone as first-line treatment for AL amyloidosis with renal involvement. Amyloid 23(1), 51\u201357 (2016).","journal-title":"Amyloid"},{"issue":"6","key":"e_1_3_3_124_2","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.clml.2019.11.005","article-title":"Cyclophosphamide, bortezomib and dexamethasone (CyBorD) for the treatment of newly diagnosed AL amyloidosis: impact of response on survival outcomes","volume":"20","author":"Diaz-Pallares C","year":"2020","unstructured":"Diaz-Pallares C, Lee H, Luider J Cyclophosphamide, bortezomib and dexamethasone (CyBorD) for the treatment of newly diagnosed AL amyloidosis: impact of response on survival outcomes. Clin. Lymphoma Myeloma Leuk. 20(6), 394\u2013399 (2020).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"4","key":"e_1_3_3_125_2","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1080\/13506129.2020.1778461","article-title":"Presence of t(11;14) in AL amyloidosis as a marker of response when treated with a bortezomib-based regimen","volume":"27","author":"Dumas B","year":"2020","unstructured":"Dumas B, Yameen H, Sarosiek S, Sloan JM, Sanchorawala V. Presence of t(11;14) in AL amyloidosis as a marker of response when treated with a bortezomib-based regimen. Amyloid 27(4), 244\u2013249 (2020).","journal-title":"Amyloid"},{"issue":"1","key":"e_1_3_3_126_2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/13506129.2020.1798224","article-title":"Timing and impact of a deep response in the outcome of patients with systemic light chain (AL) amyloidosis","volume":"28","author":"Kastritis E","year":"2020","unstructured":"Kastritis E, Fotiou D, Theodorakakou F Timing and impact of a deep response in the outcome of patients with systemic light chain (AL) amyloidosis. Amyloid 28(1), 3\u201311 (2020).","journal-title":"Amyloid"},{"issue":"4","key":"e_1_3_3_127_2","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s00380-019-01513-y","article-title":"Assessment of prognosis in immunoglobulin light chain amyloidosis patients with severe heart failure: a predictive value of right ventricular function","volume":"35","author":"Nagano N","year":"2020","unstructured":"Nagano N, Yano T, Fujita Y Assessment of prognosis in immunoglobulin light chain amyloidosis patients with severe heart failure: a predictive value of right ventricular function. Heart Vessels 35(4), 521\u2013530 (2020).","journal-title":"Heart Vessels"},{"issue":"4","key":"e_1_3_3_128_2","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1080\/10428194.2020.1849675","article-title":"Posttreatment dFLC less than 10mg\/l predicts superior organ response and longer time to next treatment in newly diagnosed light-chain amyloidosis patients treated with bortezomib","volume":"62","author":"Shen KN","year":"2020","unstructured":"Shen KN, Miao HL, Zhang CL Posttreatment dFLC less than 10mg\/l predicts superior organ response and longer time to next treatment in newly diagnosed light-chain amyloidosis patients treated with bortezomib. Leuk. Lymphoma 62(4), 874\u2013882 (2020).","journal-title":"Leuk. Lymphoma"},{"issue":"1","key":"e_1_3_3_129_2","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1182\/blood-2020-138814","article-title":"Phase 2 trial of ixazomib, cyclophosphamide and dexamethasone for treatment of previously untreated light chain amyloidosis","volume":"136","author":"Muchtar E","year":"2020","unstructured":"Muchtar E, Gertz M, Laplant B Phase 2 trial of ixazomib, cyclophosphamide and dexamethasone for treatment of previously untreated light chain amyloidosis. Blood 136(Suppl. 1), 52\u201353 (2020).","journal-title":"Blood"},{"issue":"1","key":"e_1_3_3_130_2","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood-2020-141563","article-title":"The Italian Medicines Agency prospective registry of bortezomib-based treatment in AL amyloidosis","volume":"136","author":"Palladini G","year":"2020","unstructured":"Palladini G, Milani P, Celant S The Italian Medicines Agency prospective registry of bortezomib-based treatment in AL amyloidosis. Blood 136(Suppl. 1), 22 (2020).","journal-title":"Blood"},{"issue":"3","key":"e_1_3_3_131_2","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1080\/13506129.2016.1208081","article-title":"Depression and anxiety in patients with AL amyloidosis as assessed by the SF-36 questionnaire: experience in 1226 patients","volume":"23","author":"Shu J","year":"2016","unstructured":"Shu J, Lo S, Phillips M Depression and anxiety in patients with AL amyloidosis as assessed by the SF-36 questionnaire: experience in 1226 patients. Amyloid 23(3), 188\u2013193 (2016).","journal-title":"Amyloid"},{"issue":"8","key":"e_1_3_3_132_2","first-page":"430","article-title":"Treatment tolerability in patients with immunoglobulin light-chain amyloidosis","volume":"11","author":"Rizio AA","year":"2018","unstructured":"Rizio AA, White MK, Mccausland KL Treatment tolerability in patients with immunoglobulin light-chain amyloidosis. Am. Health Drug. Benefits 11(8), 430\u2013437 (2018).","journal-title":"Am. Health Drug. Benefits"},{"key":"e_1_3_3_133_2","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2147\/PROM.S146849","article-title":"Psychometric validation of the SF-36 health survey in light chain amyloidosis: results from community-based and clinic-based samples","volume":"8","author":"White MK","year":"2017","unstructured":"White MK, Mccausland KL, Sanchorawala V, Guthrie SD, Bayliss MS. Psychometric validation of the SF-36 health survey in light chain amyloidosis: results from community-based and clinic-based samples. Patient Relat. Outcome Meas. 8, 157\u2013167 (2017).","journal-title":"Patient Relat. Outcome Meas."},{"key":"e_1_3_3_134_2","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1477-7525-7-27","article-title":"Mapping SF-36 onto the EQ-5D index: how reliable is the relationship?","volume":"7","author":"Rowen D","year":"2009","unstructured":"Rowen D, Brazier J, Roberts J. Mapping SF-36 onto the EQ-5D index: how reliable is the relationship? Health Qual Life Outcomes 7, 27 (2009).","journal-title":"Health Qual Life Outcomes"},{"issue":"1","key":"e_1_3_3_135_2","doi-asserted-by":"crossref","first-page":"5517","DOI":"10.1182\/blood-2019-124250","article-title":"Diagnostic delay and characterization of the clinical prodrome in AL amyloidosis: data from 1313 US commercially insured patients between 2006\u20132018","volume":"134","author":"Hester LL","year":"2019","unstructured":"Hester LL, Gifkins DM, Bellew KM Diagnostic delay and characterization of the clinical prodrome in AL amyloidosis: data from 1313 US commercially insured patients between 2006\u20132018. Blood 134(Suppl. 1), 5517 (2019).","journal-title":"Blood"},{"issue":"10","key":"e_1_3_3_136_2","doi-asserted-by":"crossref","first-page":"e320","DOI":"10.1016\/j.clml.2019.09.526","article-title":"Primary treatment of light chain (AL) amyloidosis with bortezomib, lenalidomide and dexamethasone (VRD) or with bortezomib, cyclophosphamide and dexamethasone (VCD\/CyBorD): efficacy and toxicity","volume":"19","author":"Kastritis E","year":"2019","unstructured":"Kastritis E, Gavriatopoulou M, Fotiou D Primary treatment of light chain (AL) amyloidosis with bortezomib, lenalidomide and dexamethasone (VRD) or with bortezomib, cyclophosphamide and dexamethasone (VCD\/CyBorD): efficacy and toxicity. Clin. Lymphoma Myeloma Leuk. 19(Suppl. 10), e320\u2013e321 (2019).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"6","key":"e_1_3_3_137_2","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/bjh.14135","article-title":"Short- and long-term outcomes of AL amyloidosis patients admitted into intensive care units","volume":"174","author":"Guinault D","year":"2016","unstructured":"Guinault D, Canet E, Huart A Short- and long-term outcomes of AL amyloidosis patients admitted into intensive care units. Br. J. Haematol. 174(6), 868\u2013875 (2016).","journal-title":"Br. J. Haematol."}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.2217\/cer-2021-0261","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,19]],"date-time":"2023-03-19T13:06:26Z","timestamp":1679231186000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.2217\/cer-2021-0261"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":135,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["10.2217\/cer-2021-0261"],"URL":"https:\/\/doi.org\/10.2217\/cer-2021-0261","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"type":"print","value":"2042-6305"},{"type":"electronic","value":"2042-6313"}],"subject":[],"published":{"date-parts":[[2022,4]]}}}